Literature DB >> 12061881

Synthesis and structure-affinity-activity relationships of novel benzofuran derivatives as MT(2) melatonin receptor selective ligands.

Valérie Wallez1, Sophie Durieux-Poissonnier, Philippe Chavatte, Jean A Boutin, Valérie Audinot, Jean-Paul Nicolas, Caroline Bennejean, Philippe Delagrange, Pierre Renard, Daniel Lesieur.   

Abstract

A series of N-(2-phenylbenzofuran-3-yl) ethyl amide and N-(2-arylalkylbenzofuran-3-yl) ethyl amide derivatives were synthesized and evaluated as melatonin receptor ligands. The affinity of each compound for the two MT(1) and MT(2) melatonin receptor subtypes was determined by binding studies using 2-[(125)I]iodomelatonin on human embryonic kidney cell line HEK293 membrane homogenates. The intrinsic activity of the most interesting compounds was evaluated on the [(35)S]GTPgammaS binding assay. Introduction of a 2-phenyl substituent in the C-2 benzofuran position leads to an agonist compound, 10q, which binds more strongly than melatonin itself to both MT(1) and MT(2) subtypes. On the other hand, a 2-benzyl group in the same position allows MT(2) antagonist selective ligands to be obtained. The MT(2) selectivity and antagonist potency can be modulated with suitable modifications on the N-acyl and benzyl substituents, and the most selective compounds 10c and 19 show affinity ratios of 123 and 192, respectively, and bind to the MT(2) subtype similarly to melatonin itself (0.1 nM). Nevertheless, 10c acts as an MT(1) and MT(2) antagonist, whereas 19 is a partial agonist.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12061881     DOI: 10.1021/jm0005252

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors.

Authors:  Margarita L Dubocovich; Philippe Delagrange; Diana N Krause; David Sugden; Daniel P Cardinali; James Olcese
Journal:  Pharmacol Rev       Date:  2010-07-06       Impact factor: 25.468

Review 2.  Physiological and metabolic functions of melatonin.

Authors:  J Barrenetxe; P Delagrange; J A Martínez
Journal:  J Physiol Biochem       Date:  2004-03       Impact factor: 4.158

3.  New selective ligands of human cloned melatonin MT1 and MT2 receptors.

Authors:  Valérie Audinot; François Mailliet; Chantal Lahaye-Brasseur; Anne Bonnaud; Aude Le Gall; Christophe Amossé; Sandra Dromaint; Marianne Rodriguez; Nadine Nagel; Jean-Pierre Galizzi; Benoît Malpaux; Gérald Guillaumet; Daniel Lesieur; François Lefoulon; Pierre Renard; Philippe Delagrange; Jean A Boutin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-05-23       Impact factor: 3.000

Review 4.  A molecular and chemical perspective in defining melatonin receptor subtype selectivity.

Authors:  King Hang Chan; Yung Hou Wong
Journal:  Int J Mol Sci       Date:  2013-09-06       Impact factor: 5.923

5.  Synthesis and functional characterization of substituted isoquinolinones as MT2-selective melatoninergic ligands.

Authors:  Yueqing Hu; King H Chan; Xixin He; Maurice K C Ho; Yung H Wong
Journal:  PLoS One       Date:  2014-12-05       Impact factor: 3.240

6.  New quinoxaline derivatives as potential MT₁ and MT₂ receptor ligands.

Authors:  Saioa Ancizu; Nerea Castrillo; Silvia Pérez-Silanes; Ignacio Aldana; Antonio Monge; Philippe Delagrange; Daniel-Henry Caignard; Silvia Galiano
Journal:  Molecules       Date:  2012-06-25       Impact factor: 4.411

7.  Antiproliferative and pro-apoptotic activity of melatonin analogues on melanoma and breast cancer cells.

Authors:  Giuliana Gatti; Valeria Lucini; Silvana Dugnani; Angela Calastretti; Gilberto Spadoni; Annalida Bedini; Silvia Rivara; Marco Mor; Gianfranco Canti; Francesco Scaglione; Annamaria Bevilacqua
Journal:  Oncotarget       Date:  2017-08-10

8.  Chiral Recognition of Flexible Melatonin Receptor Ligands Induced by Conformational Equilibria.

Authors:  Gian Marco Elisi; Annalida Bedini; Laura Scalvini; Caterina Carmi; Silvia Bartolucci; Valeria Lucini; Francesco Scaglione; Marco Mor; Silvia Rivara; Gilberto Spadoni
Journal:  Molecules       Date:  2020-09-04       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.